The decision to stop or reduce antipsychotic medication is one of the most consequential choices a person with schizophrenia can make. It is also one of the most loaded — surrounded by hope, fear, frustration, ideology, and clinical uncertainty. This article aims to lay out what is actually known: about discontinuation symptoms, about relapse risk, about supersensitivity psychosis, and about how to taper safely if reduction is the right choice.
Stopping antipsychotics often causes a mix of true withdrawal symptoms and increased risk of relapse — slow tapering with a prescriber substantially reduces both, but cannot eliminate them.
Why people consider stopping
The reasons are usually rational and worth taking seriously:
- Side effects that are intolerable (weight gain, sexual dysfunction, sedation, akathisia)
- A long period of stability and the wish to test what life feels like without medication
- Concerns about long-term effects (tardive dyskinesia, metabolic syndrome)
- Difficulty accepting the diagnosis
- Cost or access difficulties
- Pregnancy planning
None of these are unreasonable. The right response is rarely "don't even consider it" and rarely "just stop" — it is a genuine clinical conversation about risks, benefits, and how to minimise both.
What happens when antipsychotics are stopped
Three distinct things can occur, sometimes simultaneously, and confusing them is one of the central problems in this area:
1. Discontinuation symptoms
True withdrawal effects from the medication leaving the body. These are well documented, particularly for medications with strong anticholinergic or histamine activity. Symptoms include:
- Nausea, vomiting, diarrhoea
- Sweating, drooling
- Insomnia, vivid dreams
- Anxiety, restlessness
- Muscle aches, dizziness
- Flu-like symptoms
These typically appear within 1–7 days of stopping, are worst with abrupt cessation, and resolve over days to a few weeks. They are particularly common with clozapine and olanzapine.
2. Withdrawal-emergent dyskinesias
Movement abnormalities that appear after stopping. Some are transient. Some unmask underlying tardive dyskinesia that was being suppressed by the medication. See the tardive dyskinesia article.
3. Relapse of the underlying illness
This is the most consequential outcome. Relapse rates after antipsychotic discontinuation are high — across multiple studies, roughly 60–80% of patients with schizophrenia relapse within 1–2 years of stopping medication. Rates are lower in people who have had only a single episode and remained stable for years, but still substantial.
Supersensitivity psychosis
This is a more controversial concept. The theory, proposed by Guy Chouinard and others, is that long-term D2 blockade can cause the brain to upregulate dopamine receptors, so that when the medication is stopped (or reduced), there is a rebound of psychotic symptoms that is different from the original illness — often more intense, more dopamine-driven, and harder to treat. The phenomenon is best documented for tardive dyskinesia (clearly a real supersensitivity effect) and is debated for psychosis itself.
What is clear: rapid discontinuation can produce psychotic symptoms in some people, and these may be worse than what they originally experienced. Slow tapering reduces this risk significantly.
Who can consider stopping?
There is no universal answer, but the patients with the best chance of stopping safely tend to share features:
- A single episode of psychosis that responded well to treatment
- A long period of stability (typically 2+ years)
- Good insight into the illness
- Strong social support
- Ability to recognise early warning signs of relapse
- Quick access to care if relapse begins
- Absence of substance use that triggers symptoms
Patients with multiple episodes, severe initial illness, ongoing symptoms, or unstable circumstances generally do worse with discontinuation and should approach it cautiously, if at all.
How to taper safely
1. Do it with your prescriber, not alone
Stopping abruptly without telling anyone is the worst case for everyone — physically uncomfortable, higher relapse risk, and no monitoring if things go wrong.
2. Slow is better than fast
Common practice in research settings has been a 10–25% dose reduction every 1–4 weeks. More recent thinking, particularly from groups like the international Maudsley deprescribing guidelines, suggests much slower tapers — sometimes over many months or years — to allow the dopamine system to adjust gradually. The principle is "hyperbolic tapering": each step removes a smaller percentage of the receptor occupancy, so reductions get smaller as the dose gets lower.
3. Watch for early warning signs
Sleep changes, suspiciousness, mood changes, social withdrawal — the same prodromal signs that preceded earlier episodes. Tracking these in an app or journal can give a clear early signal. See our article on early warning signs.
4. Don't stop psychosocial support
If anything, increase it. CBT for psychosis, family education, and structured activity all support successful tapering. See CBTp.
5. Have a relapse plan
Agreed in advance with the prescriber: at what symptoms do you go back up on the dose? Who do you contact? What is the safety plan?
6. Don't taper during major life stress
Pregnancy, bereavement, job change, moving — these are not the times to remove a stabiliser. Wait for a calmer period.
Switching, not stopping
If a medication's side effects are the main problem, switching to a different antipsychotic is often a better path than stopping altogether. Most side effect profiles differ enough between agents that switching can solve the problem while maintaining symptom control.
Long-acting injections (LAIs)
Stopping an LAI requires special planning. Because the drug is released slowly over weeks, there is no abrupt change — but the gradual decline can produce delayed effects 2–4 weeks after the last injection. Most clinicians recommend bridging with oral medication during the transition.
When to call your prescriber
Any return of unusual thoughts, perceptions, or beliefs during a taper. Sleep changes lasting more than a few nights. Withdrawal symptoms severe enough to interfere with daily life. Pressure from yourself or others to stop "all at once." Seeking guidance is a strength, not a failure.
Honest framing
For some people, life-long antipsychotic treatment is the right answer. For some, careful reduction over years opens up a better life. For some, stopping leads to a relapse that is harder than what came before. None of these outcomes is inherent to the choice; they depend on circumstances, support, the underlying illness, and luck.
The honest framing is that stopping antipsychotics is a serious decision — neither an act of liberation nor an act of recklessness — and one that deserves the same care, planning, and clinical partnership as starting them in the first place.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.